Alain B. Schreiber has been named president and chiefexecutive of Vical Inc. of San Diego. He was senior vicepresident of discovery research at Rhone-Poulenc Rorer CentralResearch. Privately held Vical's technology consists of directinjection of purified gene sequences into muscle and othertissues.
Creative Biomolecules Inc. announced that by mutualagreement Jan A. Buck will no longer serve as president, chiefexecutive and director. Buck will be a consultant to thecompany on special projects. The Hopkinton, Mass., company isdeveloping protein-based products for the repair andregeneration of human tissues.
MedImmune Inc. of Gaithersburg, Md., named David M. Mottvice president of development and planning. He was vicepresident of corporate finance at Smith Barney, Harris Upham& Co. Inc. MedImmune (NASDAQ:MEDI) is focused on vaccinesfor infectious diseases.
Wayne C. Koff, former chief of the NIH's division of AIDSvaccine research and development branch, has been namedvice president for vaccine research and development at UnitedBiomedical Inc. The privately held Hauppauge, N.Y., company isdeveloping immunoassays to screen and diagnose HIV, HTLVand hepatitis C infections.
William F. Graney has been named vice president of medicalaffairs at Alkermes Inc. He was group director of clinicalresearch at Rhone-Poulenc Rorer. Cambridge, Mass.-basedAlkermes (NASDAQ:ALKS) is developing treatments for centralnervous system disorders.
Cytogen Corp. has promoted Robert T. Maquire from director ofclinical investigations to vice president. The Princeton, N.J.,company (NASDAQ:CYTO) is developing monoclonal antibody-based diagnostics and therapeutics.
SciClone Pharmaceuticals Inc. has named David Horwitz vicepresident of medical and regulatory affairs. He was vicepresident for medical and professional affairs at BaxterHealthcare Corp. SciClone (NASDAQ:SCLN) of San Mateo, Calif., isfocused on therapeutics for life-threatening or chronicinfectious diseases, cancers and immune system disorders.
Athena Neurosciences Inc. of South San Francisco, Calif., namedJan Wallace vice president of clinical and regulatory affairs. Hewas vice president of clinical research, central nervous system,at Warner-Lambert/Parke-Davis. Athena (NASDAQ:ATHN) isfocused on therapeutics and diagnostics for neurologicaldiseases and disorders.
George H. Parsons has been named vice president of researchand development of T Cell Diagnostics Inc., a subsidiary of TCell Sciences Inc. (NASDAQ:TCEL) of Cambridge, Mass. He wasgeneral manager of the food diagnostics division of Gene-TrakSystems. T Cell Diagnostics is focused on immunology researchand diagnostic products.
Idec Pharmaceuticals Corp. of La Jolla, Calif., has named RichardW. Krawiec director of investor relations and corporatecommunications. Krawiec was managing editor of theBiotechnology Newswatch newsletter. Idec (NASDAQ: IDPH) isdeveloping immunologically active monoclonal antibodies.
Melissa Yeager has been named associate director forregulatory affairs at Liposome Technology Inc. (NASDAQ:LTIZ)She was a senior regulatory affairs associate for Alza Corp. LTIZof Menlo Park, Calif., is developing liposome and lipid-basedpharmaceutical products.
Barbara J. Weiblem has been named director of technicalservices at Boston Biomedica Inc. of West Bridgewater, Mass.She held positions in research and development at TempleUniversity Hospital, the Naval Blood Research Laboratory atBoston University School of Medicine and the University ofMinnesota. Boston Biomedica is a manufacturer and supplier ofAIDS, hepatitis and other infectious disease reagents.
(c) 1997 American Health Consultants. All rights reserved.